CA3111702C - METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT - Google Patents

METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT

Info

Publication number
CA3111702C
CA3111702C CA3111702A CA3111702A CA3111702C CA 3111702 C CA3111702 C CA 3111702C CA 3111702 A CA3111702 A CA 3111702A CA 3111702 A CA3111702 A CA 3111702A CA 3111702 C CA3111702 C CA 3111702C
Authority
CA
Canada
Prior art keywords
inhibiting
compounds
application
cancer treatment
mcm complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn - After Issue
Application number
CA3111702A
Other languages
English (en)
French (fr)
Other versions
CA3111702A1 (en
Inventor
Ziyi Wang
Chun Liang
Zhihong Jiang
Zhiling Yu
Jingrong Wang
Liping Bai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hong Kong University of Science and Technology
Hong Kong Baptist University HKBU
Macau University of Science and Technology
Original Assignee
Hong Kong University of Science and Technology
Hong Kong Baptist University HKBU
Macau University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hong Kong University of Science and Technology, Hong Kong Baptist University HKBU, Macau University of Science and Technology filed Critical Hong Kong University of Science and Technology
Publication of CA3111702A1 publication Critical patent/CA3111702A1/en
Application granted granted Critical
Publication of CA3111702C publication Critical patent/CA3111702C/en
Withdrawn - After Issue legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3111702A 2012-05-09 2013-05-09 METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT Withdrawn - After Issue CA3111702C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261644442P 2012-05-09 2012-05-09
US61/644,442 2012-05-09
CA2873283A CA2873283C (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2873283A Division CA2873283C (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Publications (2)

Publication Number Publication Date
CA3111702A1 CA3111702A1 (en) 2013-11-14
CA3111702C true CA3111702C (en) 2025-03-18

Family

ID=49551267

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3111702A Withdrawn - After Issue CA3111702C (en) 2012-05-09 2013-05-09 METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT
CA2873283A Active CA2873283C (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2873283A Active CA2873283C (en) 2012-05-09 2013-05-09 Method and compounds for inhibiting the mcm complex and their application in cancer treatment

Country Status (9)

Country Link
US (1) US11648258B2 (enExample)
EP (2) EP4248978A3 (enExample)
JP (6) JP2015517500A (enExample)
CN (2) CN110412285B (enExample)
AU (1) AU2013259486B2 (enExample)
CA (2) CA3111702C (enExample)
ES (1) ES2949335T3 (enExample)
IN (1) IN2014MN02513A (enExample)
WO (1) WO2013169989A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019283946B2 (en) * 2017-05-19 2021-05-20 Enkang Pharmaceuticals (Guangzhou), Ltd. Crystal characteristics, preparation processes and anticancer applications of 17beta-neriifolin crystal forms
CN108948119B (zh) 2017-05-19 2023-11-21 恩康药业科技（广州）有限公司 黄夹次甙乙多晶型的晶型特征、制备方法及在抗癌上的应用
CN114177189A (zh) * 2019-03-27 2022-03-15 天津中医药大学 黄夹次乙苷作为抗肿瘤药物的应用
WO2025077888A1 (zh) * 2023-10-13 2025-04-17 恩康药业科技（广州）有限公司 一种适合外用的化合物及药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0592990A (ja) 1991-08-06 1993-04-16 Taisho Pharmaceut Co Ltd カルデノライド誘導体
WO2002014343A1 (en) 2000-08-17 2002-02-21 Terness, Peter Bufadienolide derivatives and use as immunosuppressive, antiinflammatory and analgesic agents
US8318922B2 (en) 2002-08-29 2012-11-27 The Hong Kong Polytechnic University Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
US7393950B2 (en) 2002-08-29 2008-07-01 Hong Kong University Of Science & Technology Antisense oligonucleotides targeted to human CDC45
JP2004131435A (ja) * 2002-10-11 2004-04-30 Mitsubishi Chemicals Corp 抗癌剤のスクリーニング方法及び組織の癌化の判定方法
DE10248751A1 (de) 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
US20070207120A1 (en) * 2004-04-14 2007-09-06 Sarah Drayton Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6
US20090022708A1 (en) 2004-12-22 2009-01-22 Lobie Peter E Trefoil Factors and Methods of Treating Proliferation Disorders Using Same
EP1787645A1 (en) 2005-11-18 2007-05-23 Institut Curie New method for treating cancer based on the modulation of the calcineurin and/or the calcineurin/NFAT pathway
US20090018088A1 (en) * 2006-10-27 2009-01-15 University Of Louisville Research Foundation Treating cancer with cardiac glycosides
CN101683359B (zh) * 2008-09-28 2012-05-09 上海秀新臣邦医药科技有限公司 一种治疗肿瘤的中药组合物及其制备方法
CN101726577A (zh) * 2008-10-13 2010-06-09 中山大学 通过干扰巢蛋白表达来筛选抑制肿瘤增殖和促进细胞凋亡的药物的方法
WO2010068247A1 (en) 2008-12-10 2010-06-17 Sloan-Kettering Institute For Cancer Research Cardenolides for the treatment of ocular cancer
CN102219821A (zh) 2011-05-05 2011-10-19 沈阳药科大学 一类强心苷类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
AU2013259486A1 (en) 2014-12-18
EP4248978A2 (en) 2023-09-27
EP2846807A4 (en) 2016-07-27
CA3111702A1 (en) 2013-11-14
EP2846807B1 (en) 2023-06-07
CA2873283C (en) 2021-05-04
US20150099712A1 (en) 2015-04-09
WO2013169989A1 (en) 2013-11-14
AU2013259486B2 (en) 2019-12-12
JP2021193132A (ja) 2021-12-23
JP2025169320A (ja) 2025-11-12
EP2846807A1 (en) 2015-03-18
ES2949335T3 (es) 2023-09-27
EP4248978A3 (en) 2023-11-08
CN104736157A (zh) 2015-06-24
JP2020073544A (ja) 2020-05-14
JP2018100274A (ja) 2018-06-28
IN2014MN02513A (enExample) 2015-07-17
JP2024001049A (ja) 2024-01-09
EP2846807C0 (en) 2023-06-07
JP2015517500A (ja) 2015-06-22
CN104736157B (zh) 2019-06-11
US11648258B2 (en) 2023-05-16
CN110412285A (zh) 2019-11-05
CA2873283A1 (en) 2013-11-14
CN110412285B (zh) 2022-11-15

Similar Documents

Publication Publication Date Title
MY197809A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
GB2519906A (en) Methods and systems for detecting biological components
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
GB2531881A (en) Method of isolating circulating tumor cells
MX367042B (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer.
PH12012502128B1 (en) Chemical compounds
WO2014018563A3 (en) Methods for the treatment of cancer
EP3800253A3 (en) Prostate cancer detection kit or device, and detection method
MX352617B (es) Compuestos triciclicos fusionados como inhibidores de cinasa raf.
EP2911691A4 (en) PROCESS FOR TREATING NEUROENDOCRIN TUMORS WITH WNT PAD BINDERS
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
MY207247A (en) Detection of chromosome interaction relevant to breast cancer
PH12016500580A1 (en) Conjugated antibodies against ly75 for the treatment of cancer
EP3100046A4 (en) Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
EA201401201A1 (ru) Способ
PT2825633T (pt) Método para cultivar células de e. coli para alta densidade
MX393754B (es) Metodos y composiciones para inhibir cnksr1
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
CA3111702C (en) METHOD AND COMPOUNDS FOR THE INHIBITION OF THE MCM COMPLEX AND THEIR APPLICATION IN ANTICANCER TREATMENT
EP3199638A4 (en) Cancer cell detection method using cells of biological origin
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
PH12014502461A1 (en) Biomarkers for iap inhibitor therapy
IN2012DE00794A (enExample)
AU2013204740A1 (en) Methods of treating cancer using angiogenin or an angiogenin agonist

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210310

AZWI Withdrawn application

Effective date: 20210611

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310

EEER Examination request

Effective date: 20210310